Elsevier purchases oncology portfolio

Elsevier purchased Cancer Information Group's (CIG) oncology journal portfolio for an undisclosed sum. The acquisition, which includes six titles, will leave the journals' editors and editorial boards unchanged; David Allen, formerly CIG's managing editor, is now managing editor at Elsevier.
“The CIG titles are attractive because they provide high-quality peer-reviewed content—which Elsevier will seek to further improve in partnership with the editorial teams—in this dynamic area of research and clinical practice,” said Tom Reller, Elsevier's VP, global corporate relations, in an email. “Oncology is an important growth area for Elsevier, with increasing disease incidence, new therapeutic options for patients, and increasing numbers of papers published each year,” he said.
The titles, which include Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer and Clinical Genitourinary Cancer, will be available online and in print, with advertising opportunities available in both formats, Reller said.
Glen Campbell, EVP, global medical research, Elsevier, said in a statement that “Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.